Circulating tumor DNA (ctDNA), small pieces of DNA released from dying tumor cells into the bloodstream, can be easily and non-invasively identified and ex | Cancer ...

A new study presented at the International Association for the Study of Lung Cancer 2025 World Conference on Lung Cancer ...

Large B-cell lymphomas (LBCL) are curable, but patients with residual disease after therapy invariably experience progression. Ultrasensitive methods to detect circulating tumor DNA (ctDNA) as minimal ...

Tumor-informed circulating tumor DNA (ctDNA) has shown promise as a biomarker for treatment response monitoring (TRM) in a variety of tumor types, with the potential to improve clinical outcomes. We ...

Clinical study on the assessment of first-line drug efficacy in advanced gastric cancer by monitoring circulating tumor cells through a self-developed microfluidic chip. This is an ASCO Meeting ...

The ongoing BioMolCTC trial will further investigate the role of combined ISET ® CTC-DNA and ctDNA in the minimal residual disease (MRD) setting. Rarecells also plans to assess how its new approach ...

Researchers hope the advanced warning could enable earlier, less invasive treatments with fewer side effects and better ...

Circulating tumor DNA (ctDNA) is emerging as a promising biomarker to predict treatment response in patients with metastatic renal cell carcinoma (mRCC). In a recent study, Alan Tan, MD, of Vanderbilt ...

A new study from Karolinska Institutet, published in Nature Communications, reveals that cyclin-dependent kinases (CDK) ...

Think of them as medical detectives, helping doctors detect issues at the genomic level before they become life-threatening ...